Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

2008 ◽  
Vol 110 (1) ◽  
pp. 65-70 ◽  
Author(s):  
David Scott Miller ◽  
John A. Blessing ◽  
Diane C. Bodurka ◽  
Albert J. Bonebrake ◽  
John O. Schorge
Keyword(s):  
Phase Ii ◽  
Phase Ii Study ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Second Line ◽  
Oncology Group ◽  
Second Line Chemotherapy ◽  
Recurrent Carcinoma ◽  
Line Chemotherapy

Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study

2006 ◽  
Vol 103 (2) ◽  
pp. 523-526 ◽  
Author(s):  
Paula M. Fracasso ◽  
John A. Blessing ◽  
Kelly L. Molpus ◽  
Lisa M. Adler ◽  
Joel I. Sorosky ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Second Line ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document